Grace Therapeutics, Inc.: Form 20-F for the period ended Mar 31, 2018
Filed with the SEC on Jun 29, 2018 and accepted by EDGAR at Jun 29, 2018, 11:35 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 12 months2017-04-01 to 2018-03-31 | −CAD 19.7m | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months2017-04-01 to 2018-03-31 | −CAD 21.5m | ifrs-full:ProfitLoss |
| Operating cash flow | 12 months2017-04-01 to 2018-03-31 | −CAD 12.5m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2017-04-01 to 2018-03-31 | CAD 455.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2018-03-31 | CAD 8.2m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2018-03-31 | CAD 9.5m | ifrs-full:CurrentAssets |
| Total assets | At period end2018-03-31 | CAD 23.0m | ifrs-full:Assets |
| Current liabilities | At period end2018-03-31 | CAD 6.7m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2018-03-31 | CAD 14.7m | ifrs-full:Liabilities |
| Shares outstanding | At period end2018-03-31 | 25,638,215 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001171843-18-004911. Last ingested by Listed: Nov 14, 2026, 23:10 ET. Listed shows no prices and gives no investment advice.